2 hours HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) MarketBeat
HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Tuesday.
HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Tuesday.